Ramucirumab in advanced hepatocellular carcinoma in REACH-2: the true value of α-fetoprotein

被引：49

作者：

Zhu, Andrew X. ^{[1
]}

Finn, Richard S. ^{[2
]}

Galle, Peter R. ^{[3
]}

Llovet, Josep M. ^{[4
,5
]}

Kudo, Masatoshi ^{[6
]}

机构：

[1] Harvard Med Sch, Massachusetts Gen Hosp, Canc Ctr, Boston, MA 02114 USA

[2] Univ Calif Los Angeles, Geffen Sch Med, Los Angeles, CA USA

[3] Univ Med Ctr, Mainz, Germany

[4] Icahn Sch Med Mt Sinai, New York, NY 10029 USA

[5] Hosp Clin Barcelona, Inst Invest Biomed August Pi & Sunyer, Barcelona, Spain

[6] Kindai Univ, Osaka, Japan

来源：

LANCET ONCOLOGY | 2019年 / 20卷 / 04期

关键词：

D O I：

10.1016/S1470-2045(19)30165-2

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：E191 / E191

页数：1

共 6 条

[1] Ramucirumab and the controversial role of α-fetoprotein in hepatocellular carcinoma [J].

Abou-Alfa, Ghassan K. .

LANCET ONCOLOGY, 2019, 20 (02) :177-179

[2] Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial [J].

Bruix, Jordi ;

Qin, Shukui ;

Merle, Philippe ;

Granito, Alessandro ;

Huang, Yi-Hsiang ;

Bodoky, Gyrogy ;

Pracht, Marc ;

Yokosuka, Osamu ;

Rosmorduc, Olivier ;

Breder, Valeriy ;

Gerolami, Rene ;

Masi, Gianluca ;

Ross, Paul J. ;

Song, Tianqiang ;

Bronowicki, Jean-Pierre ;

Ollivier-Hourmand, Isabelle ;

Kudo, Masatoshi ;

Cheng, Ann-Lii ;

Llovet, Josep M. ;

Finn, Richard S. ;

LeBerre, Marie-Aude ;

Baumhauer, Annette ;

Meinhardt, Gerold ;

Han, Guohong .

LANCET, 2017, 389 (10064) :56-66

[3] Survival Analysis over 28 Years of 173,378 Patients with Hepatocellular Carcinoma in Japan [J].

Kudo, Masatoshi ;

Izumi, Namiki ;

Sakamoto, Michiie ;

Matsuyama, Yutaka ;

Ichida, Takafumi ;

Nakashima, Osamu ;

Matsui, Osamu ;

Ku, Yonson ;

Kokudo, Norihiro ;

Makuuchi, Masatoshi .

LIVER CANCER, 2016, 5 (03) :190-197

[4]

National Cancer Institute, NCI DICT CANC TERMS

[5] Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study [J].

Rimassa, Lorenza ;

Assenat, Eric ;

Peck-Radosavljevic, Markus ;

Pracht, Marc ;

Zagonel, Vittorina ;

Mathurin, Philippe ;

Caremoli, Elena Rota ;

Porta, Camillo ;

Daniele, Bruno ;

Bolondi, Luigi ;

Mazzaferro, Vincenzo ;

Harris, William ;

Damjanov, Nevena ;

Pastorelli, Davide ;

Reig, Maria ;

Knox, Jennifer ;

Negri, Francesca ;

Trojan, Jorg ;

Lopez, Carlos Lopez ;

Personeni, Nicola ;

Decaens, Thomas ;

Dupuy, Marie ;

Sieghart, Wolfgang ;

Abbadessa, Giovanni ;

Schwartz, Brian ;

Lamar, Maria ;

Goldberg, Terri ;

Shuster, Dale ;

Santoro, Armando ;

Bruix, Jordi .

LANCET ONCOLOGY, 2018, 19 (05) :682-693

[6] Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial [J].

Zhu, Andrew X. ;

Kang, Yoon-Koo ;

Yen, Chia-Jui ;

Finn, Richard S. ;

Galle, Peter R. ;

Llovet, Josep M. ;

Assenat, Eric ;

Brandi, Giovanni ;

Pracht, Marc ;

Lim, Ho Yeong ;

Rau, Kun-Ming ;

Motomura, Kenta ;

Ohno, Izumi ;

Merle, Philippe ;

Daniele, Bruno ;

Shin, Dong Bok ;

Gerken, Guido ;

Borg, Christophe ;

Hiriart, Jean-Baptiste ;

Okusaka, Takuji ;

Morimoto, Manabu ;

Hsu, Yanzhi ;

Abada, Paolo B. ;

Kudo, Masatoshi .

LANCET ONCOLOGY, 2019, 20 (02) :282-296

← 1 →